Literature DB >> 22787204

Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A.

Joydip Bhanja Chowdhury1, Shubham Shrivastava, Robert Steele, Adrian M Di Bisceglie, Ranjit Ray, Ratna B Ray.   

Abstract

We have examined the underlying mechanism of hepatitis C virus (HCV)-mediated IFITM1 regulation. IFITM1 is a potential target of miR-130a. Our results demonstrated that miR-130a expression was significantly higher in HCV-infected hepatocytes and liver biopsy specimens than in controls. Introduction of anti-miR-130a in hepatocytes increased IFITM1 expression. Hepatocytes stably expressing IFITM1 reduced HCV replication. Together, these results suggested that HCV infection of hepatocytes upregulates miR-130a and that use of anti-miR-130a may have potential for restriction of HCV replication.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787204      PMCID: PMC3446586          DOI: 10.1128/JVI.00882-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

Review 2.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

Authors:  Witold Filipowicz; Suvendra N Bhattacharyya; Nahum Sonenberg
Journal:  Nat Rev Genet       Date:  2008-02       Impact factor: 53.242

3.  Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity.

Authors:  Peng Ru; Robert Steele; Eddy C Hsueh; Ratna B Ray
Journal:  Genes Cancer       Date:  2011-07

4.  Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells.

Authors:  R L Friedman; S P Manly; M McMahon; I M Kerr; G R Stark
Journal:  Cell       Date:  1984-10       Impact factor: 41.582

5.  Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection.

Authors:  Verena Bihrer; Mireen Friedrich-Rust; Bernd Kronenberger; Nicole Forestier; Jörg Haupenthal; Ying Shi; Jan Peveling-Oberhag; Heinfried H Radeke; Christoph Sarrazin; Eva Herrmann; Stefan Zeuzem; Oliver Waidmann; Albrecht Piiper
Journal:  Am J Gastroenterol       Date:  2011-05-24       Impact factor: 10.864

6.  MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells.

Authors:  Robert Steele; Justin L Mott; Ratna B Ray
Journal:  Genes Cancer       Date:  2010-04-01

7.  MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Heike Varnholt; Uta Drebber; Falko Schulze; Inga Wedemeyer; Peter Schirmacher; Hans-Peter Dienes; Margarete Odenthal
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

8.  Nomenclature and numbering of the hepatitis C virus.

Authors:  Carla Kuiken; Peter Simmonds
Journal:  Methods Mol Biol       Date:  2009

Review 9.  miRNAs in human cancer.

Authors:  Thalia A Farazi; Jessica I Spitzer; Pavel Morozov; Thomas Tuschl
Journal:  J Pathol       Date:  2010-11-18       Impact factor: 7.996

10.  Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Silvia Cermelli; Anna Ruggieri; Jorge A Marrero; George N Ioannou; Laura Beretta
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

View more
  57 in total

Review 1.  RNA viruses and microRNAs: challenging discoveries for the 21st century.

Authors:  Gokul Swaminathan; Julio Martin-Garcia; Sonia Navas-Martin
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

2.  A sorting signal suppresses IFITM1 restriction of viral entry.

Authors:  Kun Li; Rui Jia; Minghua Li; Yi-Min Zheng; Chunhui Miao; Yunfang Yao; Hong-Long Ji; Yunqi Geng; Wentao Qiao; Lorraine M Albritton; Chen Liang; Shan-Lu Liu
Journal:  J Biol Chem       Date:  2014-12-19       Impact factor: 5.157

Review 3.  MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature.

Authors:  Paul Ravi Waldron; Mark Holodniy
Journal:  Diagn Microbiol Infect Dis       Date:  2014-06-05       Impact factor: 2.803

Review 4.  Post-transcriptional regulation of interferons and their signaling pathways.

Authors:  Ram Savan
Journal:  J Interferon Cytokine Res       Date:  2014-04-04       Impact factor: 2.607

5.  Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway.

Authors:  Anupam Mukherjee; Adrian M Di Bisceglie; Ratna B Ray
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

Review 6.  Role of circulatory microRNAs in the pathogenesis of hepatitis C virus.

Authors:  Iqra Almas; Samia Afzal; Muhammad Idrees; Muhammad Usman Ashraf; Iram Amin; Muhammad Shahid; Khadija Zahid; Sadia Zahid
Journal:  Virusdisease       Date:  2017-11-27

7.  Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies.

Authors:  Jing Shen; Abby B Siegel; Helen Remotti; Qiao Wang; Regina M Santella
Journal:  Hepatoma Res       Date:  2016-06-01

8.  The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry.

Authors:  Sumudu K Narayana; Karla J Helbig; Erin M McCartney; Nicholas S Eyre; Rowena A Bull; Auda Eltahla; Andrew R Lloyd; Michael R Beard
Journal:  J Biol Chem       Date:  2015-09-09       Impact factor: 5.157

9.  MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.

Authors:  Takayoshi Shirasaki; Masao Honda; Tetsuro Shimakami; Rika Horii; Taro Yamashita; Yoshio Sakai; Akito Sakai; Hikari Okada; Risa Watanabe; Seishi Murakami; MinKyung Yi; Stanley M Lemon; Shuichi Kaneko
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

Review 10.  Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Masato Nakamura; Tatsuo Miyamura; Shingo Nakamoto; Arup Banerjee; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.